- Biotechnology
- Thursday, 28 Nov 2019
Jubilant Biosys Commences Major Capacity Expansions for its Drug Discovery Services Business
Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Lifesciences Limited, today announced commencement of two expansion projects in Greater Noida and Bengaluru.
Due to growing customer demand for its range of functional and integrated drug discovery services, Jubilant Biosys has started design and construction of brand new and state-of-the-art chemistry services laboratories on the existing Jubilant Greater Noida site. The chemistry FTE capacity will be doubled and operations are expected to commence from H2 2020. The new site can accommodate up to 500 Chemistry FTE's. The site will be designed for the highest global compliance standards and deliver superior speed and quality in the entire drug discovery process.
Jubilant Biosys has obtained a 10-acre plot in the Devanahalli Industrial Park which is adjacent to the International Airport. A completely new drug discovery services site will be constructed in phases for further expansions.
In addition, we have formed a new digital business unit comprising of Bio-Informatics, Data-curation for AI/ML, TrialStat EDC software as well as discovery focussed AI/ML capabilities. This business unit will also further expand on the new site and deliver increased benefits to our customers.
Marcel Velterop, President – Jubilant Biosys and CDMO, said: "The improving customer confidence earned through exemplary scientific execution and a positive outlook in the global drug discovery industry has resulted in the largest investment program in Jubilant Biosys since its inception. We will soon be able to offer our customers much improved capacity and services as well as ability to deliver an integrated IND package along with superior functional discovery services. A combination of the best talent and state-of-the-art technology and instrumentation will be offered to pursue drug discovery collaborations and help deliver new innovation to patients faster than ever. "
Related Industry Updates
AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors
Jun 01, 2020
Companion Animal Diagnostics Market is expected to reah US$ 6,303.87 million by 2030
Nov 02, 2023
Global Small Molecule Anti-Tumor Targeted Drug Market 2020-2027 Comprehensive Study By Key Players Abbott Laboratories, Cytokinetics Inc., Bayer HealthCare AG, OncoGenex Pharmaceuticals Inc., Hospira Inc
Apr 05, 2021
US Blood Bank Market Trends, Business Strategies and Opportunities With Key Players Analysis 2027
Sep 09, 2020
Middle East and Africa Organoids market is expected to Rise US$ 141.26 million in 2027
Mar 15, 2021
Dermatological Products Market Growing Demand and Growth Opportunity
Apr 26, 2021
Asia Pacific Catalyst Fertilizers Market 2019-2027| High Tech Industry Report with Top Companies Like Clariant, DuPont de Nemours, Haldor Topsoe, Johnson Matthey
Jan 19, 2021